What is Alzheimer’s Disease

Ballard, Gauthier, Corbett, Brayne, Aersland, et al (2011) defined the condition as an irreversible, progressive brain illness that gradually destroys an individual's thinking and memory skills, and eventually the ability to perform even the most basic tasks, interfering with the person's daily life. The illness is currently the sixth leading cause of death in the United States. However, current estimates indicate that the condition may be the third leading cause of death in the elderly, after cancer and heart disease. The disease Alzheimer’s was given the name after a German psychiatric specialist Dr. Alios Alzheimer who noted fluctuations in the middle-aged dementia patient brain contrasted to that of the healthy man. The disease metamorphoses he detected are presently acknowledged as the disease characteristic (Gazzaniga & Mangun 2014). Alzheimer’s sickness is a progressive disorder of the brain and a type of dementia that explains for 80% of dementia occurrences, becoming the most generic variety of dementia amongst aged people. Dementia is the loss of cerebral operational, thinking, and retention, as well as developmental skills. Its acuteness differs from the placid phase, in the initial stage when it starts to alter a person’s brain functionality, to the later critical juncture, at this point individuals with the condition fully depend on the support of others for major daily life activities. Dementia causative factors vary, reliant on the types of variations in changes in human brain activity. Common types of dementias are; vascular dementia, frontotemporal conditions and Lewy body dementia (Ballard et al.2011). Typically, individuals can have two or more combination of conditions nonetheless dementia must be amongst the pattern, which is characterized by hybrid dementia. For example, individual may have both vascular dementia and Alzheimer's disease.

What are the Symptoms?

Alzheimer’s is a condition where the brain deteriorates which ultimately damages the brain functionality. Brains are compound and distinctive to for every person. Therefore, it is essential to consider that individuals who have Alzheimer's might not disclose the precise similar indications of the condition. Nevertheless, there are common signs that distinguish Alzheimer’s syndrome (Smith 2015).

Individuals begin to experience Alzheimer in a memory lapse, and in the initial stages of Alzheimer’s the indicators are relatively benign and negligible. Most cases of incidents for individuals with this condition can have burden recalling are:

Problems with memorizing a person’s name or a conversation word for word

Difficulty in recalling most current conversation

unable to remember special events like centenaries or schedules which they have arranged (Burns and Iliffe, 2009)

The mentioned example are issues that can be assumed as a normal aging process since from time to time we tend to forget the same problems. Conversely, the memory loss symptoms are distinctively conspicuous and steady linked to normal aging signs. In the later stages of the disorder, the symptoms turn out to be more visible. Furthermore, in advance, the brain functionality may reduce its operative ability and individuals who have Alzheimer's breed exertions in information processing. (Alzheimer’s Association, 2016). Some illustrations are:

Difficulty in decision making, problem-solving and task concentration

Reduced spatial judgment, for instance, estimating distance or areas navigation becomes a challenge

Conversation engagement becomes challenging since individuals can miss course and go over conversation all over again (Hebert et al. 2001).

These symptoms come about for the premature impairment in Alzheimer's is typical of a brain section known as the hippocampus, which has a vital function in everyday retention. Life events memories that occurred from the past is frequently unaltered in the earlier disease phases (Lyketsos et al.2011). Loss of memory due to Alzheimer's disease progressively hinders with day-to-day life during the advancements of the condition. These individuals sometimes:

misplace things around the house such as keys, wallets, eyeglasses

strain to get the proper terms during talks or be unable to remember someone even a close relative

Fail to recall current exchanges or happenings

lose their way in accustomed places or on a recognizable journey

Fail to remember engagements or occasions (Querfurth and LaFerla, 2010).

Granting those retention problems are regularly one of the first Alzheimer's, symptoms individuals with the condition will similarly suffer – or continue to progress – difficulties with other aspects of judgment, cognitive, sensitivity or interaction with various elements. They may struggle with complications including:

language – straining to track a dialogue or recapping the conversation

Visio-spatial complications wrong estimation of depth and length or sighted things in three-dimensional form; stairs navigation or car parking come to be considerably difficult

focusing, scheduling or consolidation – Challenges posed in decision-making, problem-solving or execution of a tasks sequence for instance meal preparation

coordination – being chaotic or falling behind time (Burns and Iliffe, 2009).

Individuals in the prior Alzheimer's phases will frequently have moods fluctuations. They quickly develop anxiousness, short-tempered or dispirited. Several people are introverted and low concentration in events and leisure pursuit.

For individuals with Alzheimer’s, it is a difficult emotional time for them since they are faced with individuality loss and communication inability. Mood changes are regularly conspicuous, mainly in the primary phases individuals having indicators of nervousness, dispirited and short-tempered mannerism (Lyketsos et al., 2002).

Advanced phase

While in the progressive stages of the disease symptoms can be seen more clearly as they become critical, Alzheimer’s patient require extra support and attention in their daily activities. In the advancement of Alzheimer’s memory shortfall problem, communication, cognitive and coordination is entirely damaged. Some Individuals begin to imagine things that do not exist(hallucinations) or sometimes perceive things that are not present. (Hebert et al. 2001) Several Alzheimer's patients correspondingly with time grow some weird manners that appear strange. These take account of getting agitated for example having anxiety or walking up and down, yelling, recapping the similar subjects during a conversation, distracting patterns of sleeping or responding violently. These kinds of reaction sometimes are disturbing or severe for these individuals and their caregivers. These possibly calls for special attention and control for their loss of memory. In the developing phases, persons with the disease might end up being considered a lesser amount of awareness of their surroundings and events. They may have troubles taking food or with mobility when they are on their own, and in the end gradually fragile. Ultimately, these individuals will require assistance through their entire day-to-day activities (Querfurth and LaFerla, 2010).

What are the tests used to assess Alzheimer’s?

Physicians apply some approaches and means to the determination of whether or not the persons are suffering from memory loss and possibly finding out if the problem is related to Alzheimer’s dementia or the probability of a person having dementia. On behalf of patients who have Alzheimer's condition or a linked to memory loss, no distinct examination can instantaneously evaluate extents of its operational entirely. Such assessments aim at bettering our understanding on the definite treatments ability to come up with an all-inclusive, applied evaluation which is easily managed by a medical expert (Bai, Tang and He, 2000).

In the diagnosis of Alzheimer’s, specialists often:

Inquire from close relation of the individuals with the on the general health, previous medical condition, capacity to perform day-to-day works, and behavioral changes and nature of the person

Carry out examinations on memory, solving problem ability, concentration ability, calculating, and communication

Performing average medical checks, for instance, blood and urine analyses, in identification further potential bases of the disease

Undertaking brain X-rays, for example, computed tomography, positron-emission tomography or magnetic resonance imaging to dismiss new likely grounds for the disease signs (Grundman and Thal, 2000).

The examinations are done repetitively to offer physicians evidence on how the memory of an individual as well as other cerebral functionalities is fluctuating throughout the period. Alzheimer's disease can be detected once death has occurred, by connecting all the pathological processes with a brain tissue analysis in postmortem findings.

Tests of the Laboratory include:

Thyroid Stimulating Hormone

Serum electrolytes

Complete Blood Count

Glucose

Blood Urea Nitrogen tests

Drug levels for instance digoxin, Therapeutic “Diagnostic” Tests

Eliminate potentially wrong prescriptions

Treatment of trauma (Bai et al. 2000).

Once examination has been concluded, and other likely illnesses discounted then the GP can arrive at final analysis. Making a diagnosis of the disease is a complicated procedure besides if any person is involved in the exploitation of symptoms of Alzheimer’s they must review the study with their general practitioner (Grundman and Thal, 2000). The general health expert overseeing the evaluation of Alzheimer’s should examine multiple consideration to derive to a finding. Usually, GP’s should test:

Neurological tests

Cerebral function

Psychiatric evaluation

Comprehensive medical record

Sampling of blood and urine

Physical check-up

Cerebral fluid test lumbar puncture

Medical imagery, for instance, MRI and PET (Ballard et al.2011).

What Causes Alzheimer’s

During an examination of dementia patients brain, Dr. Alios Alzheimer noted alterations of the brain in contrast to the healthy brain. The central modifications he studied were accumulations of plaque on the outer and inner parts of the cells of the brain (Gazzaniga & Mangun 2014). On the cells outer side, the plates are called the amyloid plaques, in details, they are impenetrable proteins located in the middle of neurons. Those Plaques located in the cells interiors are known as neurofibrillary tangles which are protein strands or tangles situated inside cortical neurons (Gazzaniga & Mangun 2014). The plaques sited in Alzheimer’s is accountable for prevalent neuronal weakening, initiating the stoppage of brain cells proper functioning and in due course fail completely (Gazzaniga & Mangun 2014). The plaque accumulation leads to brain size decrease owing to the cell deterioration. Parts that are characteristically altered is the hippocampus, that concerned with the cortex as well as memory encompassing tasks such as sensory systems for communication (Gazzaniga & Mangun 2014). It is entirely not known the real cause of Alzheimer’s, and the accumulation of plaque in the cells of the brain is the only explanation at the moment. A different root of the Alzheimer’s is heredities. Various persons with Alzheimer’s suffer from the later inception of disease form whereby signs become more apparent in the mid-60s. The Apo lipoprotein E (APOE) genetic factor is contained in final stages of Alzheimer’s. This genetic factor has numerous manifestations. One of them, APOE ε4, escalates a person’s risk of progressing the condition as well as it is related to the previous ages of ailment inception. Nonetheless, bearing the APOE ε4 gene type never necessitate that a person would certainly acquire Alzheimer’s condition since distinct persons without APOE ε4 can as well acquire the illness. Healthiness, settings as well as the standard of living are key players that impact to Alzheimer’s. Studies propose that some aspects past heredities could take part in the advancement and Alzheimer’s ailment course. There is enormously greater interest, for instance, in the connection amongst reasoning degeneration and vascular disorders for example disease of the heart, stroke, and high blood pressure, along with metabolic disorders for instance diabetes and obesity. Current exploration will aid the health population recognize whether and how dropping threat causes for these illnesses might similarly lessen the Alzheimer’s risk.

Who does Alzheimer’s affect?

Any person is able to be affected by Alzheimer’s, however overall it is an illness that is related to age. Several factors combined is related to developing Alzheimer’s disorder. A number of risk factors can be controlled such as lifestyles although others like genes and age cannot be controlled. The group of people that can easily develop the disease include:

Age: Alzheimer’s condition most probably always affects persons of age 65 and above. Before the age of 65, a person can develop what is referred to as early-onset Alzheimer’s, but this is not very common. As the age increases, so do other kinds of dementia and the risk of Alzheimer disorder, affecting approximately 1 out of 14 people who are above 65 of age and 1 in 6 persons over the age of eighty. Although, 1 out of 20 people of age 40-65 is affected by Alzheimer’s disease (Burns and Iliffe, 2009)

Gender: Approximately among the affected persons over 65, twice as many women as men are affected by Alzheimer’s condition, although there is no clear reason for the difference. The disparity is not completely clarified by the fact that females on average live longer compared to males. This can be that lack of hormone estrogen in women following menopause is associated with Alzheimer's in women (Smith, 2015).

Genetic Inheritance: another group of people who are most likely to be affected by the disease is those whose family have a history of the illness. Although, few families have a very clear inheritance of the condition to one generation to the next generation. Families like that have a tendency to develop dementia before age 65, though it is extremely rare to identify a strongly inherited Alzheimer's disease. The result of genetics on the risk of Alzheimer's illness is very complex among the majority of persons. Many genes are known to reduce or increase the probability of a person to develop the disease. A person is at a great chance of developing the disorder, in any case, she or he has close relatives such as siblings or parents diagnosed with Alzheimer's when over 65. Although, it does not imply that the disease unavoidable, through living a healthy lifestyle, each and every individual can avoid Alzheimer’s. A group of individuals with Down’s syndrome is the ones who have a greater likelihood of acquiring the illness as a result of genetic factors. Genetic factors tend to have less effect on risk aspects for the whole populace (Smith, 2015).

Health and Lifestyle: Diseases like depression, diabetes, high cholesterol and hypertension may raise the probabilities of developing Alzheimer’s. In order to reduce the risk of developing the condition, one can make healthy choices regarding mental health, physical activities as well as diet. Therefore, these should be always kept under control. One likely risk factor for dementia is depression, and it is important to treat it early. Persons who implement healthy living specifically from mid-life onwards, have fewer chances of developing the illness. This implies drinking in moderation, eating healthy balanced diet, avoiding smoking and regularly exercising (Alzheimer’s Association, 2016).

Is there treatment for Alzheimer’s?

Alzheimer’s has no cure currently. It is fortunate that the disorder does ultimately result in severe loss of dependence, the function then finally death possibly from complications from other diseases. However, the rate that the disorder develops differ from an individual to another, and the treatment for those living with Alzheimer is to offer better well-being as well as quality life. Recent methods concentrate on assisting other persons in delaying or slowing sown symptoms, managing behavioral symptoms and maintaining mental function (Spector et al. 2012). United States Food and Drug Administration have agreed on many drugs that can assist in treating Alzheimer’s symptoms. rivastigmine (Exelon®), galantamine (Razadyne®) and Donepezil (Aricept®) are utilized to treat mild to moderate Alzheimer’s. While donepezil can also be used to treat severe Alzheimer’s. To treat moderate to severe Alzheimer’s, Memantine (Namenda®) is applicable. These medications work through regulating the chemicals that convey messages between neurons, known as neurotransmitters. They might assist with specific behavioral problems and maintain communication skills, memory as well as thinking (Alzheimer’s Association, 2016).

Pharmaceutical treatments are recommended to assist with behavioral challenges like anxiety as well as depression and with emotional problems. Furthermore, to assist in improving brain function (Lancioni et al., 2016; Schecker et al., 2013).

Cognitive Behavioural Therapy and other Non-Pharmaceutical treatments are recently being tested to confirm if they are able to aid decrease anxiety and depression because complications can occur from the medications utilized in assisting with these illnesses (Alzheimer’s Association, 2016).Being that the brain function is diminished in people with the condition, there is an issue that cognitive therapy might fail to become effective since they might be unable to retain and process information properly, though a number of studies recommend that there are positive outcomes from this kind of therapy (Spector et al. 2012).

Moreover, therapy and medication, taking practical steps to provide assistance for persons with the disease with their daily activities and living like the use of care together with technology for reminders when they are less independent may likewise assist to improve their quality of life.

Current Understanding of Alzheimer’s

Alzheimer’s Disease Facts and Figures reported in 2017 states that the sum of payments that was used to care for people with other dementias and Alzheimer’s exceeded a quarter of a trillion dollars for the first time. Above 15million people in America offer unpaid care in the form of financial, emotional as well as physical support for the approximated 5.5 million Americans of those with the conditions despite their ages.

The Facts and Figures report indicate that straining of caregiving generates critical mental as well as physical health consequences. For instance, 35% of caregivers for persons with another dementia or Alzheimer report that as a result of care responsibilities, their health has gotten worse compared with 19% caregivers for the elderly with no dementia. In addition, anxiety and depression are more common amongst caregivers of dementia. As the number of people with Alzheimer’s continues to grow, so do the impact and cost of providing care. Whereas we have realized current growths in federal research funding as well as easy access to support services and critical care planning, there is still a crucial need provide support to the research which is able to draw people nearer to effective treatment options and eventually cure (Brookmeyer, Johnson, Ziegler-Graham and Arrighi,2007).

The report illustrates that the sum of the yearly payments for hospice care, long-term care and health care of other dementia as well as Alzheimer’s patients exceeded a quarter of a trillion dollars for the first time. Furthermore, in spite of assistance from Medicaid, Medicare as well as other sources of financial support, people with dementias or Alzheimer’s continue to incur high costs from their pockets. The average per person out-of-pocket costs for seniors with the condition is higher compared to seniors with no such diseases. Even though there has been a decrease in the number of deaths from other major causes, the recent report illustrates that there has been a significant increase in deaths among people with Alzheimer’s. Deaths from Alzheimer’s raised to 89% while that of heart diseases decreased by 14% between 200 and 2014 (Brookmeyer et al. 2007).

The study identified that persons with Alzheimer’s fear burdening their families as they continue to get older, however, lack a proper plan. For instance, 70% of these individuals fear to be not able to support themselves financially or care for themselves, although 24% have planned financially for their families in preparation for any future caregiving needs. A small number of individuals are financially prepared for the cost of taking care of persons with Alzheimer’s illness, that is made worse by the fact that most Americans lack adequate savings for retirement, and many have none. Preparing financially is a very important consideration since Alzheimer’s is the most expensive illness affecting seniors. These added burdens of Alzheimer’s care on families that have neither planned for it nor saved for basic retirement needs is going to impact them and the public healthcare system directly. With a big section of the populace of America reaching high-risk years for Alzheimer’s, we’re entering a crisis.

References

Alzheimer's Association. (2011). 2011 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association, 7(2), 208.

Bai DL, Tang XC, He XC (2000) Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem 7:355-374.

Ballard C, Gauthier S, Corbett A, Brayne C, Aersland D, et al (2011) Alzheimer's disease. Lancet377: 1019-1031

Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer’s disease. Alzheimer's & dementia, 3(3), 186-191.

Burns A, Iliffe S (2009) Alzheimer's disease. BMJ 338: b158.

Gazzaniga, M. S, Ivry, R. B, & Mangun, G. R. (2014). Cognitive neuroscience : the biology of the mind. Fourth edition. New York: W. W. Norton & Company, Inc.

Grundman, M., & Thal, L. J. (2000). Treatment of Alzheimer's disease. Neurologic clinics, 18(4), 807-827.

Hansen, R. A., Gartlehner, G., Webb, A. P., Morgan, L. C., Moore, C. G., & Jonas, D. E. (2008). Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clinical interventions in aging, 3(2), 211.

Hebert, L. E., Scherr, P. A., McCann, J. J., Beckett, L. A., & Evans, D. A. (2001). Is the risk of developing Alzheimer's disease greater for women than for men?. American journal of epidemiology, 153(2), 132-136.

Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Sigafoos, J., D’Amico, F., Renna, C., & Pinto, K. (2016). Technology-Aided Programs to Support Positive Verbal and Physical Engagement in Persons with Moderate or Severe Alzheimer’s Disease. Frontiers in Aging Neuroscience, 8, 87. http://doi.org/10.3389/fnagi.2016.00087

Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., ... & Miller, D. S. (2011). Neuropsychiatric symptoms in Alzheimer’s disease.

Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the Cardiovascular Health Study. JAMA: Journal Of The American Medical Association, 288(12), 1475-1483. doi:10.1001/jama.288.12.1475

Munoz, D. G., & Feldman, H. (2000). Causes of Alzheimer's disease. Canadian Medical Association Journal, 162(1), 65-72.

Querfurth HW, LaFerla FM (2010) Alzheimer's disease. New Engl J Med362: 329-444.

Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiological reviews, 81(2), 741-766.

Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science, 298(5594), 789-791.

Smith, G. S. (2015). Handbook of Depression in Alzheimer’s Disease. Amsterdam: IOS Press.

Spector, A., Orrell, M., Lattimer, M., Hoe, J., King, M., Harwood, K., … Charlesworth, G. (2012). Cognitive behavioural therapy (CBT) for anxiety in people with dementia: study protocol for a randomised controlled trial. Trials, 13, 197.